• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·EBO.AX
Share

EBOS Group Limited Stocks

A$ 17.31Last Updated 01.07.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

A$ 2.37B

A$ 17.31
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EBOS Group Limited, established in 1922 and headquartered in Docklands, Australia, operates as a prominent marketer, wholesaler, and distributor of a broad spectrum of healthcare, medical, pharmaceutical, and animal care products. Its operations span Australia, New Zealand, and Southeast Asia, structured primarily around its Healthcare and Animal Care divisions. The Healthcare segment offers a comprehensive suite of services and products. These include intricate healthcare logistics, medication management systems, and specialized pharmacy management software. The software solutions cover various aspects such as loyalty programs, generics management, regulatory compliance, business intelligence, and in-store retail operations. EBOS also provides strategic health communications, targeted programs, and expert consultancy. The company is committed to delivering community-focused healthcare initiatives and supplies an extensive array of wellness products, including vitamins, minerals, supplements, herbal teas, natural oral care items, and functional foods like molasses and manuka honey. For independent pharmacies, EBOS offers the "Pharmacy Choice" integrated retail program and "healthSAVE," a community pharmacy banner aimed at bolstering retail business performance. Its client roster for health and wellness products is diverse, encompassing public and private hospitals, day surgery centers, general practices, aged care facilities, specialist clinics, government bodies, and non-profit health agencies, alongside critical clinical supplies. Additionally, EBOS extends its pharmacy services to various institutions, including private and public hospitals, cancer treatment centers, correctional facilities, and veterinary clinics. Further specialized offerings comprise allograft solutions, extensive healthcare distribution and warehousing services, clinical trial management and logistics, product registration support, as well as aesthetic healthcare devices, medical-grade cosmeceuticals, injectables, and a full range of surgical devices and medical consumables. Within the Animal Care segment, EBOS provides a wide selection of pet nutrition, treats, cleaning, and grooming products and accessories. It also functions as a significant wholesaler of veterinary products, catering to companion animals, livestock (production animals), and equine athletes. The company was originally incorporated as Early Bros Dental & Surgical Supplies Ltd. before adopting its current name, EBOS Group Limited, in 1986.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EBO.AX is 26 and suggests 51.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.07.2026 02:53

"Outlook Uncertain": Wall Street Revises Nike Estimates Following Earnings Report

02.07.2026 01:26

"Major Rotation": Investors Are Selling Off Chipmakers' Stocks After a Strong Rally

02.07.2026 00:33

Just 10 stocks accounted for nearly all of the Nasdaq-100's gains in the first half of the year

01.07.2026 23:42

Emerging-market currencies have erased their year-to-date gains amid a strengthening dollar

01.07.2026 23:12

SpaceX Has Developed Its Own "AI Gadget" — WSJ

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026